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Abstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with 
moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic 
in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of 
moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with 
cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in 
treating moderate to severe AD. It also covers current research into other dementias including 
but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine 
for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that 
merits further research on several topics. Clinicians should be aware of new studies and potential 
uses of memantine because of its safety and efficacy.
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Introduction
Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist 
with moderate affinity. Memantine was discovered in 1968 and patented by Eli Lilly. 
Merz later developed it in collaboration with Neurobiological Technologies, Inc. It was 
then licensed to Forest laboratories for development in the United States as well as 
Lundbeck for other international markets. The following are the proprietary names for 
memantine: Axura® and Akatinol® (Merz), Namenda® (Forest Laboratories), Ebixa® 
and Abixa® (Lundbeck), and Memox® (Unipharm).1
Prior to the approval of memantine, treatment of Alzheimer’s disease (AD) was 
limited to cholinesterase inhibitors (ChEI) for patients in the mild to moderate stages. 
There was no approved therapy for moderate to severe AD. New therapies for AD 
were eagerly pursued because of the rising numbers of patients suffering from the 
disease and progressing into the later stages. Due to the characteristic symptoms and 
progression of the disease, pathways involved in cognition, memory, and learning are 
commonly pursued as potential targets for treatment.
Mechanism of action
A central mechanism in learning and memory is long-term potentiation (LTP). LTP 
is mediated by the neurotransmitter glutamate via the NMDA receptor. The NMDA 
receptors can be found diffusely throughout the brain. However, they densely popu-
late the dendrites of pyramidal cells in the hippocampus and cortex (areas known 
to be involved in cognition, learning, and memory). In addition to the relationship Clinical Interventions in Aging 2009:4 368
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between LTP and learning, elevated glutamate levels are 
associated with excitotoxicity. Chronic low-dose administra-
tion of NMDA receptor agonists have been shown to induce 
apoptosis2,3 while high doses induce necrosis.3 The activation 
of glutamate receptors has also been found to induce the 
release of glutamate. Thus, a large build-up of glutamate 
can occur and induce a massive accumulation of Ca2+, lead-
ing to apoptosis.4 It was also noted that amyloid-beta (AB) 
plaques increase a neuron’s vulnerability to excitotoxicity.5 
AB plaques, a pathological feature of AD, were found to 
induce depolarization of astrocytes, extracellular accumu-
lation of glutamate, and intracellular deposition of Ca2+.6 
Therefore, the glutamate-induced excitotoxicity pathway 
made an excellent target for the therapy of AD.
Under physiologic conditions, the glutamate released 
by neurons is metabolized or taken up by neighboring cells. 
When these pathways are disrupted, the accumulated gluta-
mate overexcites the NMDA receptor and induces pathology 
characteristic of neurodegenerative diseases. NMDA recep-
tors act as a calcium [II] ion (Ca2+) channel that activates when 
bound by glycine, glutamate, and/or NMDA. However, the 
channel functions only when the cell membrane is depolarized 
due to the blockade of the channel by the magnesium [II] ion 
(Mg2+). This prevents the influx of Ca2+ when the neuron is 
at rest. Under pathological conditions, such as a chronically 
depolarized membrane, Mg2+ leaves the channel and neuronal 
metabolism is inhibited, leading to cell death.7 When this 
happens, the Ca2+ influx is unrestricted for a longer period of 
time than normal. This influx of Ca2+ contributes to an altera-
tion of cell function, leading to cell death either through free 
radicals8 or through overload of the mitochondria, resulting in 
free radical formation, caspase activation, and the release of 
apoptosis-inducing factors.9 Antagonists to the NMDA vary 
in affinity and in site of action, resulting in different altera-
tions to the channel. Regardless of the mechanism of action, 
antagonists decrease the permeability of the channel and 
prevent an influx of Ca2+. Thus NMDA receptor antagonists 
are looked to as possible neuroprotective agents and potential 
therapies for neurodegenerative disease.
Most NMDA antagonists are competitive antagonists 
and are not well tolerated by patients due to side effects, 
which can include hallucinations and schizophrenia-type 
symptoms.9 The side affects likely result from the competitive 
antagonists blocking physiological functions of the NMDA 
receptor. Its role in cognition, memory, and learning make 
it necessary that any drug using the NMDA receptor as a 
target of action must preserve physiologic function to be 
therapeutically useful.
Memantine acts on activated NMDA receptor by binding 
to a site located in the channel of the receptor.10 Memantine 
is a fast-binding antagonist which binds to the channel in a 
pseudo-first order manner. However, it is also dissociates 
from the receptor quickly and in a concentration indepen-
dent manner.10 This allows the dose to affect the binding of 
memantine without affecting its removal from the site of 
action and allowing for increased potency with minimal side 
affects. In comparison with other antagonists, memantine 
has a much faster course of action and thus has less effect on 
physiologic mechanisms. For this reason, memantine offers 
a lot of promise in the therapy of neurodegenerative disease 
because it will preserve physiological function.11 In addition, 
the uncompetitive nature of the memantine’s mechanism of 
action makes its antagonistic activity more potent in areas 
with massive activation of NMDA receptors.11 Memantine’s 
mechanism of action is also voltage-dependent, which leads 
to the removal of the memantine blockage by depolariza-
tion of the membrane.12 All of these characteristics make 
memantine a strong candidate for treating pathology induced 
by excitotoxicity.
In several studies, memantine was found to prevent neu-
ronal death induced via excitotoxic mechanisms.13,14 In 2003, 
memantine was approved for the treatment of moderate to 
severe AD in the US and in Europe. Approval for memantine 
permitted it to be used alone or in combination with ChEI. 
While it is currently in use for the therapy of moderate to 
severe AD, other diseases and disorders are potential targets 
for therapy with memantine.
Memantine in moderate  
to severe AD
Three randomized, double-blind, placebo-controlled 
(RDBPC) trials were submitted to the FDA in the New Drug 
Application.15–17 These studies demonstrated memantine’s 
safety and efficacy in moderate to severe AD.
The first of the studies submitted to the FDA evaluated 
memantine as a therapy for AD in a long-term care setting.15 
In a placebo-controlled trial, patients were selected accord-
ing to DSM-III criteria, a Mini-Mental State Examination 
(MMSE) score 10, and a Global Deterioration Scale 
(GDS) score of 5–7 (n = 166). The primary efficacy mea-
sures were the patient’s response to therapy functionally 
and globally using the Behavioral Rating Scale for Geriatric 
Patients (BGP) and the Clinical Global Impression of 
Change (CGI-C). Administering 10 mg/day (half the cur-
rent recommended dosage) of memantine for 12 weeks, they 
documented statistically significant improvement in global Clinical Interventions in Aging 2009:4 369
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and functional parameters. The measurements for behavior 
were not statistically significant. They also used Ferm’s 
D-test as a secondary variable to determine efficacy and 
found that the treated patients needed less time for nursing 
care due to improved functionality. While no behavioral 
improvement was noted, the global and functional improve-
ment demonstrated its value as a potential therapy for patients 
with moderate to severe AD.
In 2003, Reisberg et al conducted a similar study in an 
outpatient setting.16 These data were also submitted to the 
FDA. They used similar selection criteria with the addition 
of satisfying the diagnostic criteria of the National Institute 
of Neurologic and Communicative Disorders and Stroke and 
the Alzheimer’s disease and Related Disorders Association 
(NINCDS-ADRDA). They administered memantine 10 mg 
twice daily for 28 weeks at 32 US centers (n = 181). The study 
used the Severe Impairment Battery (SIB), the Clinician’s 
Interview-Based Impression of Change plus Caregiver Input 
(CIBIC-Plus) as primary efficacy variables for cognition 
and global measurements, respectively. Secondary efficacy 
measures included the Alzheimer’s Disease Cooperative 
Study Activities of Daily Living Inventory modified for 
severe dementia (ADCS-ADLsev) and the Neuropsychiatric 
Inventory (NPI) to measure impact on behavior. Patients 
receiving memantine showed statistically significant benefits 
when compared to placebo in both of the primary efficacy 
measures, the SIB and the CIBIC-Plus, over the 28-week trial. 
The patients receiving memantine also showed statistically 
significant improvement over placebo in the ADCS-ADLsev 
but not in the NPI. These results confirmed the results of the 
previous study with the addition of better cognitive outcomes 
for patients receiving memantine.
The third and final study submitted to the FDA was for 
a combination therapy of memantine and donepezil. Tariot 
et al17 conducted a RDBPC trial using 404 outpatients already 
on donepezil, from 37 US centers for 24 weeks with 322 
patients completing the trial. Patients were selected accord-
ing to the NINCDS-ADRDA diagnostic criteria for AD. 
They were also selected for MMSE scores between 5 and 
14, age of at least 50 years and CT scans consistent with 
AD. Primary efficacy variables included cognition, using the 
SIB, and global measures, using the CIBIC-Plus. Secondary 
outcome measures were behavioral and functional. These 
were measured using the NPI and BGP, respectively. All 
patients remained on donepezil with half randomized to the 
addition of memantine and half to the addition of placebo. 
At the conclusion of the study, statistically significant benefits 
were found in all primary and secondary endpoint measures 
in favor of donepezil/memantine vs donepezil/placebo. 
Similar results were found in a study by van Dyck et al.18 This 
confirmed previous studies with the addition of improvement 
in behavioral outcomes.
Combination therapy is a promising choice of therapy 
for patients with moderate to severe AD. It is not currently 
approved by the FDA to treat mild AD with memantine so 
ChEI are the principal choice for treatment in mild cases. 
It has been shown that transition from a ChEI to memantine 
is well tolerated,19 but better outcomes may be achieved in 
patients receiving combination memantine/ChEI17 so clini-
cians should add memantine to the patient’s treatment plan 
without discontinuing the ChEI.
However, these principal studies showed conflicting out-
comes on behavioral measurements. While Tariot et al dem-
onstrated a positive outcome,17 Reisberg et al and Winblad 
et al had no statistically significant outcomes in measures of 
behavioral outcomes.15,16 Despite this inconsistency, meman-
tine is a useful treatment for patients with moderate to severe 
AD, but with behavioral disturbances common in patients 
with AD and those disturbances causing great distress to 
care givers, great interest lies in determining if memantine 
truly improves behavioral outcomes. Wilcock et al conducted 
a pooled analysis of 3 large 6-month studies of memantine 
using the NPI as an efficacy variable. They found a statistically 
significant improvement in behavioral outcomes, especially 
in measurements of agitation/aggression.20 Gauthier et al con-
ducted a study with a shorter time period and a larger study 
group.21 This study used the NPI as well and also yielded 
statistically significant improvement in patients receiving 
memantine over those receiving placebo. These studies 
suggest that memantine may be a good treatment option for 
patients with AD and behavioral symptoms.
Finally, a study published in 2009 compiled memantine 
data from all clinical trials and from pivotal studies between 
1992 and 200816,17,23 for a post-hoc analysis.22 Patients in nurs-
ing homes or assisted living facilities were excluded because 
they have significantly different baselines. The study found 
that a meta-analysis of all the study groups showed statisti-
cally significant improvement in both the NPI and BGP for 
patients receiving memantine over placebo. However, the 
behaviors with statistically significant improvement were 
agitation/aggression, irritability/lability, and delusions. 
Perhaps more importantly, this study found a delay in the 
emergence of behavioral symptoms with memantine vs 
placebo. Improvement in these measurements and preven-
tion of emergence would ease the burden for care givers and 
increase the time to institutionalization.Clinical Interventions in Aging 2009:4 370
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A large number of patients with AD are receiving 
antipsychotics, antidepressants, anxiolytics, or neuroleptics.22 
These treatments are common due to the prevalence of 
behavioral symptoms in patients with AD. One of the most 
prevalent behavioral symptoms is agitation and aggres-
sion. Memantine attenuates these symptoms very well and 
should be considered a principle treatment for AD patients 
experiencing agitation/aggression.21,22 Further studies should 
investigate the benefits of memantine vs other treatments in 
behavioral outcomes for patients with AD.
Another critical point in the discussion of memantine as 
a treatment for AD is combination memantine/ChEI therapy. 
The study by Tariot et al demonstrated the efficacy of combi-
nation therapy in treating moderate to severe AD.17 Another 
combination therapy study, by Atri et al demonstrated a 
long-term effect of combination therapy when compared 
with patients receiving no drug therapy and patients on 
cholinesterase monotherapy.24 Primary efficacy measures 
for cognition and function were the Blessed Dementia Scale 
(BDS) and the Weintraub Activities of Daily Living Scale 
(WADL). They found that even after a mean treatment time 
of 22.5 months, patients receiving combination therapy had 
significantly better outcomes than those receiving no pharma-
cotherapy or ChEI therapy alone. These data strongly favor 
the use of memantine/ChEI combination therapy in treating 
moderate to severe AD.
For many patients and their families, who are often 
care givers as well, staying out of long-term care facilities 
is a primary goal. A recent study conducted at the 
University of Pittsburgh evaluated 943 patients with 
probable AD and followed them long-term (mean time was 
62.3 ± 35.8 months).25 They compared patients receiving 
memantine and ChEI with those receiving just ChEI and those 
receiving neither. They found that patients treated with ChEI 
had a decreased risk to institutionalization over those with 
no drug and the patients who received both memantine and 
ChEI had the greatest decrease risk (a decrease in risk over 
the ChEI monotherapy of 3.4). So while memantine/ChEI 
combination therapy may improve AD patients’ outcomes 
cognitively, functionally, behaviorally, and globally, it may 
also help patients stay at home longer and delay time to 
institutionalization.25
Other studies of memantine/ChEI combination therapy 
have shown behavioral improvements,26 functional improve-
ments,27 cognitive improvements,28,29 and a delay to institu-
tionalization.25
It should be noted that one study with memantine 
found contradicting results when compared to previous 
studies.23 This study followed a similar protocol to the 
Reisberg Study.16,23 At weeks 12 and 18, a statistically 
significant improvement was detected in the CIBIC-plus 
but not at week 24. ADCS-ADL measurements failed to 
show statistically significant improvement. The SIB did 
not show statistically significant differences either until a 
nonparametric analysis was conducted post-hoc. The sample 
population was sufficiently large but the author pointed out 
possible confounding variables for future consideration. 
In van Dyck’s study, 61% of his patients received prior ChEI 
therapy, which may have affected the outcome. A study 
comparing the response of patients grouped according to 
therapies received prior to memantine found that it affected 
the response to memantine treatment.30 van Dyck also 
pointed out that it is important to incorporate nonparametric 
analyses into the study design as a contingency plan. 
Finally, bias may be introduced utilizing the last observa-
tion carried forward (LOCF) method due to the significant 
results observed at weeks 12 and 18 but not at 24. Future 
investigations into memantine should consider previous 
therapy, nonparametric analyses, and the bias inherent in 
LOCF when designing the study.
While this conflicting study suggests some possible bias, 
many other studies have been conducted and demonstrated 
the positive effect on the progression of symptoms in patients 
with AD treated with memantine compared with placebo.31–33 
More specifically, studies compared patients with moderate to 
severe AD receiving memantine to patients receiving placebo 
and evaluated them for benefits in cognition,34 function,35 
behavior,20,21,36,37 and memory.38 In light of the abundance 
of data in support of memantine as a therapy for moderate 
to severe AD, the contradictory study should be regarded as 
critical for future studies in order to avoid the possible biases 
pointed out by the author.
While these effects, combined with previous studies’ 
results, strongly suggest the use of combination therapy in 
the treatment of moderate to severe AD, studies evaluating 
its efficacy in comparison with memantine monotherapy 
have yet to be conducted or published. It seems safe to say 
that combination therapy would be at least as effective as 
monotherapy, if not more. However, a cost/benefit analysis 
would also be an invaluable tool in decision making for 
care givers and payers. Additional studies should consider 
comparing memantine monotherapy with cholinesterase 
monotherapy.
The data above are consistent with the guidelines 
published by the American Psychiatric Association (APA) 
and the American Association for Geriatric Psychiatry Clinical Interventions in Aging 2009:4 371
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(AAGP). The guidelines recommend that clinicians 
consider the cost of treatment, severity of disease, and 
stage of progression prior to prescribing memantine. 
While data indicate that memantine is safe and effective 
as both a monotherapy and in combination with ChEI, no 
evidence suggests one is better than the other. However, 
memantine/ChEI combination therapy is more effective 
than some ChEIs alone and should be recommended over 
ChEI monotherapy.
Memantine studies in mild AD
Once an effect was seen in moderate to severe AD, the 
next logical step was to investigate mild AD. This direction 
of study has provided mixed results. In a RDBPC study, 
researchers found that memantine produced statistically 
significant improvement in cognition, global measures, 
and behavior over placebo.39 There was no statistically 
significant difference between memantine and placebo 
on functional measures. These measures were assessed 
using the ADAS-Cog, CIBIC-plus, NPI, and ADCS-ADL, 
respectively.
In addition, two 24-week studies in 2008 found no 
statistically significant difference between memantine and 
placebo in measures of cognition (ADAS-cog) or in global 
measures (CIBIC-plus).40,41 One of the studies also used 
the ADCS-ADL and NPI as secondary efficacy measures 
of function and behavior, respectively, but memantine 
was not found to have a significant improvement in these 
measures either.
However, in the Bakchine study, the patients receiving 
memantine did show statistically significant improvement vs 
the control group at weeks 12 and 18 on the ADAS-Cog, but 
not at the end of the study.41 The authors attributed the lack 
of significance at week 24 to a sudden improvement in the 
control group. The results suggest that memantine may be a 
safe and effective therapy for patients with mild to moder-
ate AD but further study is merited due to the conflicting 
studies. These future studies should include memantine/ChEI 
combination therapy and memantine vs ChEI comparison 
studies.
Consideration should be given to designing future 
studies for the use of memantine in treating mild AD. The 
uncompetitive mechanism of memantine suggests it may 
demonstrate more effect in more severe diseases. This was 
demonstrated in a study of vascular dementia (VaD) when 
one subgroup responded better than another when grouped 
according to severity.42 Because it is of lesser severity than 
moderate to severe, a longer study with a larger study group 
is needed to detect any effect that memantine may or may 
not have in mild to moderate AD. In accordance with the 
treatment guidelines of the APA and AAGP, memantine 
should not be used unless future evidence suggests it is 
effective.
Memantine in non-AD dementias
The pivotal study by Winblad et al included both AD and 
VaD patients. A statistically significant effect was detected 
in both dementias15 and further studies have elaborated 
on memantine’s efficacy in treating VaD.42–44 One of these 
studies was a 28-week study with 321 patients.43 Using the 
ADAS-cog and CIBIC-plus as primary efficacy measures, 
the study found those measures stabilized in patients 
receiving memantine in comparison with placebo-treated 
patients. In addition, the treatment was well tolerated 
and there were no concerning side effects in this study. 
Memantine shows promise for the treatment of patients 
with VaD.
The next of those studies was a pooled analysis of several 
6-month clinical trials measuring cognitive improvement 
using the ADAS-cog.42 Patients receiving memantine had 
statistically significantly better outcomes, with mild adverse 
effects. Post-hoc analysis revealed that the subgroup of VaD, 
called ‘small vessel disease,’ accounted for the outcome of 
the experimental group while the ‘large vessel disease’ sub-
group was not statistically significant when compared with 
placebo on its own. A study of memantine/ChEI combination 
therapy had similar results and conclusions.44
These studies make it clear that memantine has the poten-
tial to treat VaD but they also indicate what future studies 
need to consider. First, a group of patients diagnosed with 
VaD shows great heterogeneity and can easily be divided into 
subcategories.42,44 Second, the measures used to document the 
progression of the disease are designed for AD and may not 
be suitable for VaD. Finally, patients may suffer from both 
VaD and AD so sensitive neuroimaging of the brain may be 
necessary to screen for patients who are suffering from pure 
VaD without the amyloid plaques that are so common in AD. 
These have to be considered to validate any effect that may 
or may not be detected in future studies.
Dementia with Lewy bodies (DLB) has also been 
studied as a potential target of memantine therapy. One 
RDBPC studyshowed a statistically significant improve-
ment in cognition (MMSE) while showing no significant 
changes in the Parkinsonian or psychotic symptoms.45 
This study suggests memantine may prove useful for DLB, 
but the study was short (16 weeks) and had relatively few Clinical Interventions in Aging 2009:4 372
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subjects (n = 23). Further studies are merited to ensure the 
safety and efficacy of memantine in these patients. This 
is especially true since other small studies have shown 
adverse effects and worsening symptoms in patients with 
DLB receiving memantine.46,47
Other forms of dementia were also studied as potential 
targets of memantine therapy. One such disease is HIV-
associated dementia. A 20-week study found no statistically 
significant benefits.48 The author attributed the lack of a 
clinically significant result to the short duration of the study. 
However, they did find that indicators of neuronal metabolism 
suggest memantine may slow the destruction of neurons in 
patients with HIV .
A small study (n = 16) of Wernicke-Korsakoff syndrome 
found that patients receiving memantine showed statistically 
significant improvement in measures of cognition (MMSE) 
and function (ADCS-ADL) over patients receiving placebo 
during the course of the study (28 weeks).49 These results sug-
gest memantine could be used but a larger study is needed.
Another study considered frontotemporal dementia 
(FTD) but found mixed results in measures of behavior, 
cognition, and global status, probably due to small sample 
size (n = 16).50
The efficacy of memantine in treating any form of 
dementia in which glutamate-induced neurotoxicity is 
implicated should be considered for future study. The 
current research is limited by the small study groups so 
future studies should ensure that large numbers of patients 
are enrolled.
Other studies with memantine
Apart from dementia, many other diseases and disorders are 
associated with neurodegeneration. Studies in animals have 
suggested that memantine is neuroprotective51 but will still 
allow signaling and normal function.52,53 This is the reason 
memantine is clinically such a well tolerated drug. When 
administered to rats, researchers found it reduced neuronal 
deficits54 by blocking NMDA receptors but it did not impair 
learning.55 Thus, it shows a lot of promise in treating acute 
as well as chronic brain disease. Animal studies found 
memantine was effective in ameliorating neuronal loss in 
infarctions,56 traumatic brain injury,57 hypoxic ischemic 
brain injury,58 intracerebral hemorrhage,59 mitochondrial 
dysfunction induced cell death,60 and secondary neuronal 
damage.61
Stroke research has looked at memantine as a neuropro-
tective agent to be administered both prior to the stroke event 
and afterwards. Studies have also found that memantine can 
lengthen the window to rescue neurons after the stroke event 
even if not administered before the stroke event.62,63 While 
research is still restricted to the animal model, it shows that 
memantine lengthens the therapeutic window when mixed 
with clenbuterol in the mouse model62 or mixed with nitrites 
in the rat model.63 Another study in the rabbit model demon-
strated a potential amelioration of behavioral deficits when 
administered after a stroke event.64 These benefits are likely 
the result of memantine preventing the secondary excito-
toxicity induced by lysis of glutamate-releasing neurons in 
the initial event.
A pilot study examined memantine as a treatment for 
patients suffering from combat-related post-traumatic stress 
disorder (PTSD).65 Four patients were treated with meman-
tine and evaluated for immediate memory, delayed memory, 
hyperarousal, and depression. There was a uniform response 
in all the cases in delayed memory and variable reductions 
in hyperarousal and depressive symptoms. While the small 
study size and lack of a placebo control prevents these data 
from bearing any significance clinically, it does provide a 
rationale for further studies on using memantine as a therapy 
in patients with PTSD.
Researchers have also looked at memantine as a potential 
therapy for Parkinson’s disease (PD). Studies have shown 
potential therapeutic benefits for patients with PD treated with 
memantine.66,67 However, the mechanism of action is unclear 
and is likely independent of dopaminergic therapies.68 This 
alternative therapeutic action of memantine in PD could shed 
light on the pathology of PD if investigated further. Further 
studies are merited.
Memantine has also been considered as a potential 
analgesic for chronic pain. NMDA receptors are thought 
to be involved in stimulus-invoked pain following nerve 
damage. Many patients experience chronic pain following 
surgery, amputation, or severe trauma. Studies have now 
shown that memantine has no analgesic affect for patients 
suffering chronic pain following surgery,69 post-herpetic 
neuropathy,70 HIV-associated neuropathy,71 and cannot 
ameliorate phantom limb pain.72–74 However, memantine 
has been reported to decrease the intensity of phantom 
limb pain when administered postoperatively.72 In addition, 
patients who suffer traumatic injury to an upper extremity 
and are administered memantine show a decrease in pain and 
some cortical reorganization on a functional MRI.75 While 
further investigations into the primary analgesic affects of 
memantine on chronic pain may be unwarranted, treatment 
of complex regional pain syndrome and phantom limb pain 
with memantine merit further study.Clinical Interventions in Aging 2009:4 373
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Memantine has also been investigated as a potential 
therapy for refractory migraines.76 This study showed a 
decrease in the incidence of refractory migraines in patients 
taking memantine for a 30-month period. These positive 
results suggest that memantine is a potential therapy and 
merits further study.
Additional studies suggest memantine may possibly 
benefit patients with depression,77,78 binge eating disorder,79 
schizophrenia,80,81 autism,82,83 attention-deficit/hyperactive 
disorder (ADHD),84 nystagmus,85 Huntington’s disease,86,87 
and opioid dependence.88
In contrast, some studies suggest memantine offers 
little or no benefit to patients with tinnitus,89 cocaine 
dependence,90,91 and nicotine dependence.92
Results of studies of memantine’s efficacy in alcohol 
dependence were mixed.93–95
Several diseases and disorders are currently being studied 
in clinical trials (Table 1) or have been studied in recently 
completed trials (Table 2).
New formulation of memantine
A clinical trial has recently been completed with a new 
28 mg, slow-release memantine preparation in moderate to 
severe AD. Statistically significant benefits were seen on both 
primary efficacy measures (SIB and global). This 6-month 
RDBPC study also included a 6-month open-label follow-
up. Memantine was well tolerated with side effects similar 
to those of placebo.97
Safety profile
Current recommended dosing for memantine in patients with 
AD is 10 mg twice daily as a target dose. Dosing is increased 
at weekly increments from 5 mg once daily to 5 mg twice 
daily to 10 mg once a day, and 5 mg once a day to 10 mg twice 
daily. Studies into once daily dosing show it to be compara-
tively mild and well tolerated with similar efficacy.98
Memantine is a well tolerated drug with few patients 
receiving memantine discontinuing therapy compared 
with patients receiving placebo.15–17,23 One study found that 
approximately 10% of patients administered memantine 
experienced a fall or injury during the study.99
The following side effects occur in more than 2% 
of patients and at a greater frequency (not statistically 
significant) than in placebo-treated patients during clinical 
trials: fatigue, pain, hypertension, dizziness, headache, 
constipation, vomiting, back pain, confusion, somnolence, 
hallucination, coughing, dyspnea, agitation, fall, inflicted 
injury, urinary incontinence, diarrhea, bronchitis, 
insomnia, urinary tract infection, influenza-like symptoms, 
abnormal gait, depression, upper respiratory tract infec-
tion, anxiety, peripheral edema, nausea, anorexia, and 
arthralgia.100
Memantine has also been found to have antagonistic 
effects on type 3 serotonin receptors through the use of patch 
clamping.101 Memantine’s 5HT-3 antagonism may protect 
against the gastrointestinal side effects of ChEIs when used 
in combination therapy.
Memantine undergoes both hepatic and renal elimination. 
In patients with severe impairment of either the liver or 
kidney, clinicians should prescribe a lower dosage of 
memantine accordingly. In patients with mild to moderate 
Table 2 According to the National Institute of Health website,96 
these diseases were studied in completed clinical trials
Diseases considered in completed clinical trials
Amyotrophic lateral sclerosis AIDS dementia complex
Mild to moderate AD Depression
Lupus erythematosus Depressive disorder
Parkinson’s disease dementia Tension-type headache
Dementia with lewy bodies Binge-eating disorder
Parkinson’s disease Side effects of radiation 
therapy for brain tumors
Co-morbid alcoholism 
and depression
Neuropathy secondary 
to herpes-zoster
Schizophrenia Diabetic neuropathy
Obssessive-compulsive disorder Open-angle glaucoma
Table 1 According to the National Institute of Health website,96 
these diseases are being studied in clinical trials currently being 
conducted
Diseases being considered in current clinical trials
Aphasia resulting from stroke ADHD
Alcohol consumption Opioid and heroine dependency
Traumatic brain injury Multiple sclerosis
Moderate to severe AD Compulsive buying
Frontotemporal dementia Kleptomania
Bipolar disorder Depressive disorder
Bipolar depression Neurological symptoms 
of fragile X syndrome
Autism Huntington’s disease
Pathological gambling essential tremors
General anxiety disorder Amytrophic lateral sclerosis
Social anxiety disorder Down’s syndrome
Shizophrenia Tobacco abuse
Several types and subtypes 
of dementia
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renal impairment, no adjustment is necessary. However, 
in patients with severe renal impairment, it is recommended 
that dosage not exceed 5 mg twice daily. Drugs affecting 
renal secretion through altering the pH of the urine will 
affect memantine’s clearance. Acidic urine will increase 
the rate of clearance while urine under alkaline conditions 
will undergo clearance at 80% of the rate at physiologic 
conditions. Memantine’s bioavailability is not signifi-
cantly affected by co-administration with other drugs that 
undergo renal excretion or hepatic elimination. It does 
not significantly induce or inhibit hepatic microsomal 
enzymes.
Conclusion
Research into further uses of memantine in the therapy 
of central nervous system disorders is merited by the 
nature of the drug’s mechanism. The partial selectivity 
for antagonizing pathologically activated NMDA recep-
tors makes this drug a therapeutic candidate for many 
neurodegenerative/neuropsychiatric diseases. Future 
studies into dementias other than moderate to severe 
AD (VaD, HIV-associated dementia, DLB) are needed to 
determine memantine’s safety and efficacy in treating those 
diseases. In addition, neurodegenerative/neuropsychiatric 
disorders, such as PD, Huntington’s disease, and schizo-
phrenia need closer investigation with memantine both to 
improve clinical outcomes and to clarify the pathogenesis 
of disease. Clinicians should closely follow future research 
into memantine.
While memantine has potential to treat many different 
diseases, it should be considered early in the treatment of 
moderate to severe AD. It has strong evidence supporting its 
use both as a monotherapy and in combination with ChEI. 
Since there is a lack of other treatment options in moder-
ate to severe AD, memantine should be prescribed, barring 
intolerance or complications.
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